Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) modeling and simulations, which were used to inform the pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chi‐Chung, Voss, Tiffini, Kowalski, Ken, Yang, Bei, Kleijn, Huub Jan, Jones, Christopher J., Bosch, Rolien, Michelson, David, DeAngelis, Matthew, Xu, Yang, Xie, Iris, Kothare, Prajakti A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214662/
https://www.ncbi.nlm.nih.gov/pubmed/31758661
http://dx.doi.org/10.1111/cts.12730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214662/
https://www.ncbi.nlm.nih.gov/pubmed/31758661
http://dx.doi.org/10.1111/cts.12730

Ejemplares similares